Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Dual inhibition of HSF1 and DYRK2 impedes cancer progression
by
Nicely, Lynden G.
, Allmeroth, Kira
, Wiley, Sandra E.
, Banerjee, Sourav
, de la Vega, Laureano
, Tandon, Vasudha
, Quinn, Jean
, Denzel, Martin S.
, Edwards, Joanne
, Moreno, Rita
in
Apoptosis
/ Breast cancer
/ Cancer
/ Cancer therapies
/ Cell death
/ Cytotoxicity
/ Gene expression
/ Gene Expression Regulation
/ HSF1 protein
/ Humans
/ Kinases
/ Malignancy
/ Molecular Bases of Health & Disease
/ Multiple myeloma
/ Neoplasms
/ Patients
/ Penicillin
/ Pharmacology & Toxicology
/ Phosphorylation
/ Post-Translational Modifications
/ Proteasome 26S
/ Proteasome inhibitors
/ Proteasome Inhibitors - pharmacology
/ Proteasomes
/ Proteins
/ Signaling
/ Stem cells
/ Substrates
/ Transcription factors
/ Transcription Factors - genetics
/ Transcription Factors - metabolism
/ Tumors
/ Tyrosine
/ Xenotransplantation
2023
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dual inhibition of HSF1 and DYRK2 impedes cancer progression
by
Nicely, Lynden G.
, Allmeroth, Kira
, Wiley, Sandra E.
, Banerjee, Sourav
, de la Vega, Laureano
, Tandon, Vasudha
, Quinn, Jean
, Denzel, Martin S.
, Edwards, Joanne
, Moreno, Rita
in
Apoptosis
/ Breast cancer
/ Cancer
/ Cancer therapies
/ Cell death
/ Cytotoxicity
/ Gene expression
/ Gene Expression Regulation
/ HSF1 protein
/ Humans
/ Kinases
/ Malignancy
/ Molecular Bases of Health & Disease
/ Multiple myeloma
/ Neoplasms
/ Patients
/ Penicillin
/ Pharmacology & Toxicology
/ Phosphorylation
/ Post-Translational Modifications
/ Proteasome 26S
/ Proteasome inhibitors
/ Proteasome Inhibitors - pharmacology
/ Proteasomes
/ Proteins
/ Signaling
/ Stem cells
/ Substrates
/ Transcription factors
/ Transcription Factors - genetics
/ Transcription Factors - metabolism
/ Tumors
/ Tyrosine
/ Xenotransplantation
2023
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Dual inhibition of HSF1 and DYRK2 impedes cancer progression
by
Nicely, Lynden G.
, Allmeroth, Kira
, Wiley, Sandra E.
, Banerjee, Sourav
, de la Vega, Laureano
, Tandon, Vasudha
, Quinn, Jean
, Denzel, Martin S.
, Edwards, Joanne
, Moreno, Rita
in
Apoptosis
/ Breast cancer
/ Cancer
/ Cancer therapies
/ Cell death
/ Cytotoxicity
/ Gene expression
/ Gene Expression Regulation
/ HSF1 protein
/ Humans
/ Kinases
/ Malignancy
/ Molecular Bases of Health & Disease
/ Multiple myeloma
/ Neoplasms
/ Patients
/ Penicillin
/ Pharmacology & Toxicology
/ Phosphorylation
/ Post-Translational Modifications
/ Proteasome 26S
/ Proteasome inhibitors
/ Proteasome Inhibitors - pharmacology
/ Proteasomes
/ Proteins
/ Signaling
/ Stem cells
/ Substrates
/ Transcription factors
/ Transcription Factors - genetics
/ Transcription Factors - metabolism
/ Tumors
/ Tyrosine
/ Xenotransplantation
2023
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Dual inhibition of HSF1 and DYRK2 impedes cancer progression
Journal Article
Dual inhibition of HSF1 and DYRK2 impedes cancer progression
2023
Request Book From Autostore
and Choose the Collection Method
Overview
Preserving proteostasis is a major survival mechanism for cancer. Dual specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) is a key oncogenic kinase that directly activates the transcription factor heat-shock factor 1 (HSF1) and the 26S proteasome. Targeting DYRK2 has proven to be a tractable strategy to target cancers sensitive to proteotoxic stress; however, the development of HSF1 inhibitors remains in its infancy. Importantly, multiple other kinases have been shown to redundantly activate HSF1 that promoted ideas to directly target HSF1. The eventual development of direct HSF1 inhibitor KRIBB11 suggests that the transcription factor is indeed a druggable target. The current study establishes that concurrent targeting of HSF1 and DYRK2 can indeed impede cancer by inducing apoptosis faster than individual targetting. Furthermore, targeting the DYRK2-HSF1 axis induces death in proteasome inhibitor-resistant cells and reduces triple-negative breast cancer (TNBC) burden in ectopic and orthotopic xenograft models. Together the data indicate that cotargeting of kinase DYRK2 and its substrate HSF1 could prove to be a beneficial strategy in perturbing neoplastic malignancies.
Publisher
Portland Press Ltd The Biochemical Society,Portland Press Ltd
This website uses cookies to ensure you get the best experience on our website.